An illegal drug may hold the key to a “fairy-tale” ending for patients suffering from post-traumatic stress disorder (PTSD), anxiety, addiction or depression. The drug is 3,4-methylenedioxymethamphetamine (MDMA), or ecstasy, and it reduces anxiety and fear by suppressing the amygdala. At the same time, MDMA promotes a sense of well-being and social bonding by increasing the amounts of dopamine, serotonin, oxytocin and prolactin found in the body. The only trouble is, ecstasy has been banned by the FDA since 1985, and as a Schedule I drug, is very difficult to get permission to use in clinical trials, not to mention mainstream clinical practice.
One scientific research group, the Multidisciplinary Association for Psychedelic Studies Continue reading “PTSD: Another Victim of the Drug War”